Quinolinic acid (QA) is an N-methyl-D-aspartate agonist that has been shown to produce neurotoxic effects that mimic certain neurodegenerative diseases when administered to laboratory animals. Intrastriatal injections of QA in rats have been used extensively to produce some of the neuropathological and behavioral deficits that are analogous to Huntington's disease (HD). However, acute intrastriatal injections of QA produce symptoms that are not analogous to the progressive nature of HD. Thus far, models using chronic administration of QA that produce HD-like behavioral and neuroanatomical changes have necessitated the use of a relatively bulky and fragile microdialytic pump apparatus. The present study tested an alternative way of chronically administering QA. Specifically, this study tested whether gradual release of QA from ethylene vinylacetate (EVA) polymers could produce symptoms analogous to HD. Rats received either no implants or bilateral intrastriatal implants of polymers with or without QA. Subsequent tests for spontaneous motor activity (SMA), grip strength, balance, and learning ability in a radialarm-water-maze task revealed QA-induced impairments in balance and learning ability, but did not affect grip strength or SMA. Histological analysis revealed QA-induced enlargement of lateral ventricles, striatal atrophy, and striatal neuronal loss, with relative sparing of NADPH-diaphorase-positive neurons. These results suggest that QA released from polymers can produce behavioral and neuropathological profiles analogous to early stages of HD and that EVA polymers offer a useful means of chronically delivering QA in rodent models of neurodegeneration.
INTRODUCTION
Quinolinic acid (QA) is an N-methyl-D-aspartate agonist that, when administered to animals, produces neurotoxic effects which can simulate various aspects of neurodegenerative diseases, including Alzheimer's disease (7, 21, 30 ), Parkinson's disease (29) , and, more commonly, Huntington's disease (3, 5, 34, 38) . The use of QA in animal models of HD has been well established and has been shown to mimic such HD-like symptoms as hyperactivity (34) , learning deficits (6, 11, 17) , and loss of neurons (39) when injected into the striatum of rats. Acute intrastriatal injections of QA in rats have been shown to destroy medium-sized spiny neurons that contain GABA and substance P (3) while sparing afferent fibers (38) and large cholinergic interneurons (15) , simulating a neuropathological profile analogous to what is observed in HD. Whether or not these acute intrastriatal QA injections can also mimic the HD-like sparing of medium aspiny neurons that contain NADPH-d is controversial. Some investigators have reported sparing of these neurons (3, 4, 5) , while others have reported no such sparing (8, 12, 27, 39) following acute intrastriatal injections of QA.
Because QA does not readily cross the blood-brain barrier, it needs to be administered directly into the brain, usually via acute injections, for use in most animal models of neurodegeneration. The shortcoming of using acute injections is that they usually do not mimic the progressive nature of most neurodegenerative diseases, and they often produce effects that are not analogous to the disease. For example, acute intrastriatal administration of QA often produces transient seizure activity, such as tonic-clonic forepaw movements and barrel rotations, which are not considered to be analogous to what occurs in HD (28, 34) . In addition, acute administration of QA often does not produce consistent sparing of NADPH-d-containing striatal neurons. These shortcomings have prompted investigators to seek ways to deliver QA chronically.
One method of chronically delivering QA was developed by Bazzett and colleagues (1) . They developed a device consisting of a microdialytic probe connected to a subcutaneously implanted osmotic pump that slowly infuses QA into the striatum over a 3-week period. They found that this method of QA delivery produced a HD-like neuroanatomical profile, including sparing of NADPH-d-containing striatal neurons, without inducing anomalous seizure activity (2) . In addition, they observed transient hyperactivity during the first week of QA administration, but not during the following two weeks of administration or during the subsequent three weeks after the pumps were removed (2). More recently, Shear and colleagues (40) have observed spatial reference and working memory deficits in a radialarm-water-maze (RAWM) task when rats were given chronic administration of QA using this microdialytic pump mechanism.
Although the chronic delivery of QA using the microdialytic pump apparatus provides important advances over the acute QA model, there are certain limitations with this model. For example, the microdialytic pump apparatus is relatively bulky, containing cannulae and attached tubing that protrudes from the skull. Although the apparatus seems to be tolerated relatively well by the rats, the bulkiness of the cannulae and protruding tubes may interfere with the full range of mobility in the rats and may limit the scope of behavioral testing. Use of the elevated balance beam task, for example, would entail considerable risk of dislodging or damaging the apparatus if an animal fell from the beam.
To circumvent some of the limitations of the microdialytic pump apparatus, we investigated whether the use of a QA-containing polymer, implanted into the striatum, could also produce HD-like neuroanatomical and behavioral deficits. Previously, we have shown that the microextrusion technique could be used to incorporate QA into polymers made from ethylene vinylacetate (EVA) with a 40% vinylacetate content (20) . These nonbiodegradable copolymers are benign in animals, producing no inflammatory responses, and are capable of delivering neuroactive substances for several months (36, 41) .
The purpose of the present study was to investigate the efficacy of QA released from EVA polymers implanted in the rat striatum in producing behavioral and neuroanatomical profiles analogous to those observed in HD. The polymers were implanted bilaterally into the striatum to allow the QA to diffuse from the pores of the polymer into the striatal parenchyma. The motor abilities of the rats were then assessed on various tasks and their spatial learning ability was assessed in the RAWM task. Subsequent neuroanatomical assessments included quantifying the number of Nissl-stained and NADPH-d-labeled striatal neurons, lateral ventricle size, striatal atrophy, and density of cytochrome oxidase labeling in the striatum.
METHODS

Polymer Preparation
The preparation of the QA-containing EVA polymers followed previously described procedures (20) . To evaluate the in vitro release kinetics from the QA polymers, the polymers were cut to 1 mm in length, weighed and subsequently placed into separate 50-ml glass jars, each containing 10 ml of 10 mM phosphate-buffered saline (PBS, pH 7.4). These jars were left at room temperature for 24 h, at which time a spectrophotometric analysis of the solution was performed. The solution was then discarded and fresh PBS was added. This cycle was repeated at regular 24-h intervals for 32 days. A Perkin-Elmer spectrophotometer was used to measure the absorption of QA (1.0 mg substance/10 ml PBS) at 267 nm.
Subjects
Seventeen male Sprague-Dawley rats, weighing approximately 320 -350 g, were housed individually in wire mesh cages with a 12-h light/dark cycle, with lights on at 0800 h. Rats had access to food and water ad libitum and were weighed daily. The rats were randomly assigned to either the QA polymer (QA) or control polymer (CON) group prior to handling. Group identity of the rats was coded throughout behavioral and histological analysis to avoid experimenter bias.
Surgery
The polymers were implanted bilaterally into the rat neostriatum. The rats were anesthetized with sodium pentobarbital (60 mg/kg), preceded by 0.1 ml of atropine sulfate to suppress mucosal secretions. Animals were placed in a Kopf stereotaxic apparatus with lambda and bregma on the same horizontal level. A stainless steel 17-gauge guide cannula was positioned with its tip at the following coordinates: AP ϭ ϩ0.5 mm, ML ϭ Ϯ2.5 mm from bregma, DV ϭ Ϫ5.0 mm from dura (31) . The polymers were inserted at the tip of the guide cannula and gently pushed down into the striatum with a 0.5-mm diameter stainless steel wire. Prior to implantation, both QA and CON polymers were soaked in a 10 mM phosphate-buffered saline (PBS) solution for 4 days, with fresh PBS added every 24 h. This was done to facilitate the release of QA and to reduce possible over-dosing effects of the initial burst of QA that is released during the first four days of soaking the polymer. Six of the CON rats were implanted with control polymers consisting of 100% EVA. Five CON rats were anesthetized but received no surgical implants. These two CON groups were subsequently combined into one control group because no significant statistical differences were found on any of the behavioral or histological measures between these two groups. An additional rat received QA-polymer implants identical to those described above, except the rat was perfused four days following the implant, and the brain was then processed using cytochrome oxidase (CyO) histochemistry.
Balance Beam Testing
The balance beam task was used to measure the ability of rats to traverse a narrow 1 ϫ 100 cm beam, suspended one meter above a foam-padded cushion (18) . All rats were gentled for five minutes daily during the five days prior to balance-beam training. Training was conducted four times a day, for five consecutive days, at 0900, 1100, 1300, and 1500 h following the procedures of Shear et al. (39) .
Postoperative balance beam testing was conducted once daily at 0900 h on postoperative days 7, 14, 21, and 28. During postoperative testing, rats were given three minutes to traverse the beam. If they did not complete the task, or if they fell off of the beam, the trial was ended, and the rats were placed back into their home cage. The dependent measures on this task were the number of footslips and latency to cross the beam.
Open Field Testing
On the day prior to surgery, and at 7, 14, 21, and 28 days after surgery, rats were placed into an automated open field testing apparatus (Chromotrack Version 1.00 Polytrack by San Diego Instruments) from 2000 to 0800 h. The open field testing boxes (45 ϫ 38 ϫ 37 cm) had two opaque sides and two transparent sides. The distance traveled was quantified by the Polytrack system connected to an IBM 486DX computer. A white noise generator set at 70 dB was used to mask any extraneous sounds.
Grip Strength Task
Grip strength was measured by recording the length of time the rat was able to hold onto a wire, 2 mm in diameter and 35 cm in length (39) . The grip strength test was conducted immediately prior to open field testing at 7, 14, 21, and 28 days after surgery.
Paw Placement Task and Swim Speed
The paw placement task (9) was used to test the visuospatial abilities of rats. Testing was conducted on postoperative days 7, 14, 21, and 28. Swim speeds were taken during the first trial of the first day of RAWM testing and on the last trial of the last day of RAWM testing, following the procedures of Shear et al. (39) . The dependent measure was the length of time it took the rat to swim the 50 cm from the channel entry to the escape platform.
Radial Arm Water Maze Testing
The water maze used in this study consisted of an eight-arm radial maze partially submerged in a water tank (10, 13, 40) . Beginning 14 days after surgery, all animals were tested in the RAWM for 14 days, using a paradigm for testing spatial working and reference memory adapted from Jarrard (23) . The rats were given four trials per day (0900, 1100, 1300, 1500 h). Escape platforms in the same four arms were raised for each trial (i.e., arms 1, 2, 5, and 7 in a clockwise manner; 40).
The dependent measures for this task were the number of reference and working memory errors. Reference memory errors (RME) were defined as initial entries into arms that never contained raised platforms. Entries into arms that had already been visited were defined as working memory errors (WME).
Histology
Following behavioral testing, all rats were transcardially perfused with 500 ml of 0.1 M PBS (pH 7.4) followed by 500 ml of 4% paraformaldehyde/0.1% glutaraldehyde in 0.1 M phosphate buffer (PB; pH 7.4). Immediately following perfusion, the brain was extracted, cryoprotected in 30% sucrose in 0.1 M PB, and cut coronally at 40 m on a freezing microtome. All sections throughout the striatum were saved and consecutive sections were processed using Nissl staining, NADPH-diaphorase (1), and CyO histochemistry (42) .
All cell counts were made bilaterally using an Olympus BH-2 microscope. NADPH-diaphorase-labeled neurons were counted throughout the entire area of the caudate putamen at ϩ1.7 mm, ϩ1.1 mm, ϩ0.5 mm, Ϫ0.1 mm, and Ϫ0.7 mm anterior/posterior from bregma (31) . Counts of Nissl-stained neurons were taken at the level nearest to the polymer implant (i.e., 0.5 mm anterior to bregma). A gridded reticle was placed over a 400 ϫ 400 m area ventral to the site of polymer implantation in the striatum and then immediately lateral to the site of cannula entry in the cortex.
Area measures of the lateral ventricles and the neostriatum were made bilaterally using Jandel SigmaScan Pro Version 2.00 software on a Gateway Pentium computer for sections at the following coordinates from bregma: ϩ1.5 mm, ϩ1.0 mm, ϩ0.5 mm, 0 mm, Ϫ0.5 mm, and Ϫ1.0 mm (31) . The area of the neostriatum was determined by subtracting the area occupied by the polymer from the total area within the following anatomical borders: the corpus callosum on the dorsal and lateral border, the lateral ventricles on the medial border, and the anterior commissures on the ventral border.
RESULTS
A two-way mixed-design analysis of variance (ANOVA) was used to compare QA and CON rats on (5) reference and working memory errors in the RAWM task. Analyses were conducted on the behavioral measures taken during the four weekly testing periods, except for the RAWM data for which daily measures were analyzed. Student's t tests were used to compare QA-treated and control rats on the following measures: (1) swim speed; (2) counts of Nissl-stained and NADPH-d-positive neurons in the neostriatum; (3) lateral ventricles area; and (4) striatal area. Because no significant bilateral differences were found on any of the histological measures, the data obtained from each side of the rat brain was combined in these analyses.
Polymer Release
Results of spectrophotometric analysis of in vitro release of QA from the EVA polymers are shown in Fig.  1 . Based on these results, the estimated in vivo release of QA from the polymers used in the present study was 875 nmol over a 14-day period.
Histology
The release of QA from the polymer produced noticeable lesions in the dorsal and central regions of the striatum (Fig. 2) . Polymers were implanted into the central region of the striatum, approximately 0.5-mm anterior to bregma, with QA-induced damage occurring primarily in the central and dorsal regions near the site of the implant (Fig. 3) . Striatal area was decreased in QA-treated brains at 1. (Fig. 4a) . Counts of Nissl-stained neurons indicated that QA caused a significant reduction in neurons near the site of implantation [t(15) ϭ Ϫ5.453, P Ͻ 0.01] (Fig. 4b) . However, there were no significant between-group differences in the number of neurons observed in the cortex, lateral to the site of 
FIG. 1.
Cumulative in vitro release of QA from EVA polymers identical to those used for the in vivo testing in this study. Before implantation, the polymers were soaked in PBS for 4 days (dashed line), when the initial burst of 370 nmol QA was released. Based on these in vitro data, a total of 875 nmol QA was estimated to be released following implantation. cannula entry [t(15) ϭ Ϫ1.767, P Ͼ 0.05]. No significant loss of NADPH-diaphorase neurons were detected in the striatum of the QA-treated rats [t(15) ϭ Ϫ0.891, P Ͼ 0.05] (Fig. 4c) . However, a significant enlargement of the lateral ventricles was observed in rats treated with QA at the following coordinates from bregma: (Fig. 4d) .
Balance Beam Performance
A 2 (treatment) ϫ 5 (day) mixed-design ANOVA revealed no significant between-group differences for latency to traverse the beam [F(1, 14) ϭ 0.021, P Ͼ 0.05] and number of footslips [F(1, 15) ϭ 0.069, P Ͼ 0.05] during preoperative training on the balance beam task.
A 2 (treatment) ϫ 4 (day) mixed-design ANOVA revealed that the QA-treated rats required more time to (Fig. 5) . Five of six QA-treated rats fell from the balance beam on postoperative day 7, but were able to complete subsequent trials. A 2 (treatment) ϫ 4 (day) mixed-design ANOVA showed that there were no significant differences between groups on the number of footslips [F(1, 9) ϭ 0.813, P Ͼ 0.05].
Grip Strength and Open Field Measures
There were no differences between groups on the grip strength task [F(1, 12) ϭ 2.306, P Ͼ 0.05] and spontaneous activity levels [F(1, 14) ϭ 0.138, P Ͼ 0.05] measured at days 7, 14, 21, and 28 after surgery.
Paw Placement Task and Swim Speeds
All rats were able to successfully complete the paw placement task on every trial before and after surgery. There were no significant between-group differences on swim speeds during the first trial of the first day of RAWM testing [t(15) ϭ Ϫ0.827, P Ͼ 0.05] or during the last trial on the last day of RAWM testing [t(15) ϭ Ϫ0.643, P Ͼ 0.05]. had significantly more reference memory errors than control rats. There was a significant day effect for both reference [F (1, 15) Fig. 6b , the effects of the QA administration resulted in significant working memory errors during the second week of testing.
Radial Arm Water Maze
DISCUSSION
The major finding in this study was that EVA polymers are capable of delivering QA in sufficient quantities to produce HD-like neuroanatomical and behavioral deficits, without producing tonic-clonic seizures and barrel rotations that are often associated with acute intrastriatal administration of QA. More specifically, the release of QA from the polymers resulted in: (1) a reduction in Nissl-stained striatal neurons; (2) loss of CyO labeling in the striatum; (3) dilation of lateral ventricles; (4) striatal atrophy; (5) relative sparing of NADPH-d striatal neurons; (6) transient motor deficits on the balance-beam task; and (7) spatial learning deficits in the RAWM task.
The neuroanatomical changes produced by the EVAreleased QA in this study was similar to those observed in previous work in which higher concentrations (i.e., 15 mM) of QA were administered via the microdialytic pump mechanism (1). Both methods produce comparable loss of cytochrome oxidase staining in the striatum after nearly a month of QA administration. In addition, both methods produced similar enlargements of the lateral ventricles and losses of Nissl-stained neurons, but without significant loss of NADPH-d-labeled neurons in the striatum. Although not extensively investigated, neither method appears to produce an obvious loss of cortical neurons, beyond the restricted mechanical damage produced by inserting the microdialytic device or the EVA implant. Beyond this mechanical damage, no loss of neurons was found near the cortical area through which the polymer was inserted. This suggests that there was no leakage of QA into this region of the cortex and that the QA damage was restricted to the striatum. These findings suggest that quinolinic acid released from the EVA polymers, like that released from the microdialytic pump mechanism, can simulate many HD-like neuroanatomical changes.
As with the neuroanatomical changes, the behavioral alterations induced by the EVA-released QA were also similar to those observed in previous work using the microdialytic pump mechanism (40) . Neither method produced sustained alterations in motor behavior, at least at the doses of QA that have been used thus far. However, transient QA-induced increases in activity levels have been reported in studies using the microdialytic pump device (2) . Although no increases in spontaneous motor activity were observed in the present study, transient motor impairments on the balance beam task were observed in rats that received EVA-released QA.
Despite the absence of sustained motor deficits, QA administration by either the polymer or the microdialytic apparatus (40) can produce significant learning impairments in the RAWM task. Specifically, QA administration via either the polymer or the microdialytic pump mechanism causes significant working and reference memory errors during the second week of testing in this spatial learning task. In this study, as with previous work using the microdialytic pump ap-
FIG. 6.
Chronic administration of QA caused an increase in spatial reference memory errors (a) during the 2-week testing period, and spatial working memory errors (b) during the second week of testing. Although the QA-treated rats learned to find two or three of the hidden platforms at near-normal rates, the persistent errors during the second week indicate an impaired ability to readily locate all four platforms. Data bars represent means, and error bars represent the SEM (*P Ͻ 0.05).
paratus (40) , the performance of the QA-treated rats follows a relatively normal learning curve, especially during the first week, when most rats learn to locate at least two or three of the hidden platforms. However, during the second week of testing, the QA-treated rats still have a difficult time learning to locate all four platforms, which is easily accomplished by control rats by this time. The lack of between-group differences in the paw placement and swim speed tests, in this study, and in the one using the microdialytic pump mechanism (40) , indicates that the QA-induced impairments in the RAWM task are mnemonic in nature, and not the result of impaired sensorimotor abilities. As such, these findings are consistent with spatial memory deficits observed in HD patients (24, 26) . Furthermore, because measurable cognitive deficits usually precede the onset of chorea in HD patients (16, 19) , our findings of significant cognitive deficits, during a time of minimal motor deficits, suggests that both the microdialytic device and the EVA polymer methods simulate some of the cognitive symptoms observed in the early stages of HD.
The similarity of our behavioral and neuroanatomical results to previous findings using the microdialytic pump mechanism suggests that both modes of administration produce QA-induced effects more gradually than what is observed in models using acute intrastriatal injections. Although the rate and amount of QA released in vivo from either the microdialytic pump apparatus or the EVA polymers remains to be determined, the results of the present study suggest that differences in the dynamics of QA release exists between these two methods. Extrapolation from the results of the in vitro QA release rates in this study suggests that the fastest rate of in vivo QA release from the polymers probably occurred during the first 2 weeks following implantation, with a gradual deceleration occurring thereafter. This hypothesis is supported by the observation of a noticeable, albeit smaller, striatal lesion in the rat that received only 4 days of EVA-released QA. In contrast, QA released from the microdialytic pump mechanism probably occurs at a steadier rate. This difference in release dynamics may account for the greater efficacy of EVAreleased QA. Specifically, the total amount of QA released by the polymers in the present study (i.e., 875 nmol) was lower than the quantity (i.e., 15 mM) needed to produce similar neuroanatomical effects using the microdialytic pump apparatus (1). In the Bazzett et al. study, a cumulative dose of QA (totaling approximately 880 nmol) released from the microdialytic pump was not sufficient to cause a significant loss of Nissl-stained neurons or a decrease in CyO-labeling in the striatum (1) . However, the 875 nmol of QA released from an EVA polymer in the present study was sufficient to cause a decrease in both the number of Nissl-stained neurons and amount of CyO staining in the striatum, while sparing NADPH-d neurons. The lower levels of QA released at a steadier rate via the microdialytic pump apparatus in the Bazzett et al. study may have allowed for sufficient activation of compensatory mechanisms early after implantation, allowing for a longerterm tolerance for the 880 nmol dose of QA.
Despite the differences in QA release dynamics between the microdialytic pump apparatus and the EVA polymer, it is important to emphasize that, at optimal doses of QA tested thus far, both methods provide a more accurate simulation of the earlier stages of HD than models using acute intrastriatal injections. Both models have shown relatively selective striatal damage, with sparing of NADPH-d-labeled neurons and significant cognitive deficits, in the absence of anomalous tonic-clonic seizure episodes and barrel rotations. However, further research using time course studies are needed to determine whether the neuroanatomical sequelae and emergence of the QA-induced behavioral deficits can simulate the progressive nature of HD.
The present results add support to previous findings showing that polymers provide a useful means of delivering substances that produce symptoms of neurological disorders in animal models, as well as vehicles for administering drugs in treating such diseases. The EVA polymer shows particular promise in this regard. It has been shown to release other neuroactive substances successfully in vivo, including phencyclidine (37), haloperidol (36) , levodopa (32, 33) , dopamine (14) , substance P (35), and nerve growth factor (22) . Other types of polymers also release substances over prolonged periods, including biodegradable polymers like lactic acid-glycolic acid copolymers, from which the drug release rate is largely dependent upon the polymer erosion rate. However, residue from the degrading polymers may produce confounding and potentially harmful effects that are circumvented by the use of EVA. Likewise, most microparticles or colloidal carriers (e.g., liposomes and synthetic polymers) are biodegradable. Unfortunately, they tend to be less stable during longer periods of storage and use, which can limit their utility. More stable polymer systems, like hydrogels that use poly(hydroxymethylmethacrylate), appear to release molecules for shorter periods of time than the EVA polymers (for review, see 25) . Further research in polymer development should lead to polymers with release and durability characteristics that are ideal for brain implantation.
In summary, the results of this study suggest that release of QA from EVA polymers may be a useful model for simulating certain aspects of neurodegenerative disorders, such as those observed in the early stages of HD. Further work, involving time course studies of the EVA-released QA effects and in vivo measures of the amount of QA released, is needed to optimize polymer size and drug release at doses and rates that can mimic different stages of neurodegen-eration. In this regard, it may prove beneficial to design a polymer that could release QA in increasing amounts over time. Such delivery mechanisms may prove useful for augmenting or accelerating the progression of symptoms in newly developed transgenic models of neurodegenerative diseases. Given the advantages of using the polymer over the microdialytic pump apparatus, such as being less bulky and less vulnerable to disruption during behavioral testing, further explorations in ways to improve the use of the polymer method are warranted.
